

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | €0.56 | €271.36 €203.52 Free shipping | |
| 270 pills | €0.65 | €235.70 €176.78 | |
| 180 pills | €0.70 | €168.35 €126.26 | |
| 120 pills | €0.82 | €130.72 €98.04 | |
| 90 pills | €0.95 | €114.87 €86.15 | |
| 60 pills | €1.08 | €87.14 €65.35 | |
| 30 pills | €1.93 | €77.23 €57.92 | |
| 20 pills | €2.67 | €71.29 €53.47 | |
| 360 pills | €0.89 | €427.84 €320.88 Free shipping | |
| 270 pills | €0.97 | €348.61 €261.46 Free shipping | |
| 180 pills | €1.07 | €257.49 €193.12 Free shipping | |
| 120 pills | €1.16 | €186.18 €139.63 | |
| 90 pills | €1.25 | €150.52 €112.89 | |
| 60 pills | €1.37 | €108.93 €81.69 | |
| 30 pills | €1.44 | €57.42 €43.07 | |
| 20 pills | €1.71 | €45.54 €34.15 |
Disclaimer: This information supports discussion with a healthcare professional and does not replace personalised medical advice. Always follow the official patient information leaflet and any instructions provided by a clinician or pharmacist.
Breast cancer remains one of the most commonly diagnosed cancers among women, and many tumours are driven by estrogen signaling. Nolvadex is the brand name for tamoxifen, a selective estrogen receptor modulator (SERM). It acts by binding to estrogen receptors and blocking estrogen activity in breast tissue, which can help slow the growth of oestrogen receptor–positive tumours.
Tamoxifen or Nolvadex is used under specialist supervision in Ireland, and the product is supplied as film-coated tablets or other authorised forms as prescribed. The exact treatment plan, including duration, is guided by the nature of the cancer, the patient’s menopausal status, and responses to therapy.
In some situations, Nolvadex may be used to reduce the risk of breast cancer recurrence after surgery or radiotherapy, or to lower the likelihood of developing new breast cancers in high-risk individuals. The decision to start therapy depends on a careful assessment of benefits and potential risks by a clinician specialized in oncology or breast care.
This information covers how Nolvadex is used, common safety considerations, practical handling, and follow-up in routine care. It is intended to support the patient’s understanding and to assist conversations with healthcare professionals.
Nolvadex is indicated for the treatment of hormone receptor–positive breast cancer in adults. In this setting, the medication interferes with estrogen effects on cancer cells, aiding disease control when used as part of a broader treatment plan.
It may be prescribed to reduce the risk of breast cancer recurrence following primary treatment such as surgery and radiotherapy, particularly in women whose tumours express oestrogen receptors. The aim in these circumstances is to prolong disease-free intervals and, where possible, survival outcomes, under careful monitoring.
Clinicians may consider Nolvadex for certain cases of metastatic breast cancer, where disease has spread beyond the original site. The decision reflects the balance between expected benefit, side effects, and patient preferences, and is guided by ongoing assessment during treatment.
In selected individuals at substantial risk of developing breast cancer, tamoxifen may be offered as a preventive option after a thorough discussion of potential benefits and harms. The suitability for prevention is determined by a clinician in the context of personal risk factors and overall health.
Before starting Nolvadex, a clinician will assess medical history, current medications, and potential contraindications. This evaluation may include information on liver function, history of血 clots, and prior treatments. Check that the product is prescribed for the appropriate indication and that packaging matches the prescribed strength and form.
The medication should be dispensed by a pharmacy under supervision, with a clear schedule for dosing and follow-up appointments. Ensure that all questions about the treatment plan, expected benefits, and potential risks are discussed with the pharmacist or prescriber, and that written information is reviewed.
Initiation occurs under the direction of a clinician, with initial follow-up arranged to assess tolerability, response, and any adverse effects. Maintain a record of doses taken and any symptoms experienced, to support ongoing management and safety monitoring.
Nolvadex is typically taken as a tablet once daily, with the precise timing determined by the treatment plan. The medication is usually taken consistently at the same time each day to help maintain stable levels in the body. It can be taken with or without food, depending on personal preference and tolerance.
Tablets should be swallowed whole with a glass of water. Do not crush, chew, or break a tablet unless explicitly advised by a clinician. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose; in that case, skip the missed dose and resume the regular schedule. Do not double up to make up for a missed dose unless instructed by a clinician.
Keep a clear dosing routine and do not alter the schedule without medical advice. If the patient is planning to change time zones or travel across borders, inform the prescriber to adjust the plan if necessary and to ensure continuity of therapy.
Storage conditions should be maintained during daily use, and any changes in packaging or appearance of the tablets should be reported to a pharmacist or clinician. If the medication is discontinued, questions about a safe stopping plan should be discussed with a clinician at the time of cessation.
Early effects during the first weeks can include hot flashes (sudden waves of warmth), night sweats, fatigue, and mild nausea or upset stomach. Some individuals may notice changes in vaginal bleeding or pattern of menses, particularly if premenopausal. These symptoms may lessen over time or persist, depending on the person and the cancer therapy context.
Tamoxifen can influence bone and lipid metabolism in some patients, and mood changes can occur. Changes in energy levels are common during chemotherapy- or hormone-based regimens and should be discussed with a clinician if troublesome or persistent.
Sensitivity to sun exposure may increase for some people; use sun protection as needed. The clinician may propose additional monitoring during the initial weeks to assess tolerability and to detect rare adverse effects early.
Regular follow-up appointments are important to evaluate treatment response, manage side effects, and adjust the plan if necessary. Any new symptoms or severe changes should be reported promptly to a healthcare professional.
Seek urgent medical help if there are signs suggestive of a serious adverse event, such as new unexplained severe symptoms or signs of a blood clot, including swelling, warmth, or redness in one leg; chest pain; or sudden shortness of breath. Sudden severe headaches with vision changes or persistent yellowing of the skin or eyes should also be reported.
Medical advice should be sought for any persistent or worsening side effects, such as severe hot flashes, persistent vomiting, significant fatigue affecting daily activity, or symptoms suggesting liver problems (for example, dark urine or pale stools, persistent abdominal pain).
Inform the treating clinician about all medicines, including over‑the‑counter products, herbal supplements, and vitamins, as some combinations can affect treatment. If pregnancy is possible or suspected, seek guidance promptly, as pregnancy requires special consideration during therapy.
Any planned dental procedures, surgeries, or hospital admissions should be discussed with the treating clinician beforehand, to coordinate management and prevent potential interactions or complications.
Store tablets at room temperature in a dry place away from direct sunlight. Keep the original packaging or tray, and protect from moisture. Do not store medicines in bathrooms or other damp areas, and keep them out of reach of children and pets.
Check the packaging for any damage and for expiry dates before use. Do not use Nolvadex beyond the expiry date or if the tablets appear discoloured or broken. If any medication is unused or expired, follow local guidance or return it to the pharmacist for safe disposal.
Carry a copy of the current prescription and a contact number for the pharmacy when travelling, and inform healthcare professionals of Nolvadex use during any medical consultations or procedures abroad. Do not take medication that belongs to another person or use someone else’s tablets for any reason.
All handling should be performed per the product’s patient information leaflet and healthcare professional instructions. If there is any confusion about storage conditions while away from home, consult a pharmacist for clarification.
Major contraindications include a known hypersensitivity to tamoxifen or any component of the product, pregnancy, and breastfeeding. Use during pregnancy may harm the developing fetus; alternative breast cancer management strategies should be discussed with a clinician. Breastfeeding during therapy is generally not advised.
Severe liver impairment or active liver disease requires careful evaluation by a clinician, as liver function may influence drug metabolism. A history of thromboembolic events (blood clots) or a high risk of clots is an important consideration, and the clinician may monitor closely or adjust the treatment plan accordingly.
Use with caution in patients with a history of endometrial changes or other estrogen-sensitive conditions, and in those receiving other therapies that influence hormone signaling. Inform the treating team about all current medications, as interactions with certain drugs may affect efficacy or safety. If any new health concerns arise during therapy, report them promptly.
Concrete contraindications and cautions can vary by individual and by local practice guidelines. Check the official leaflet and consult a pharmacist or physician for tailored advice before starting or continuing Nolvadex therapy.
When travelling, carry an adequate supply of Nolvadex in its original packaging with the prescription label. Maintain a consistent daily routine to help adherence, and plan for storage conditions in different environments. If travelling across time zones, coordinate with a clinician to adjust dosing timing if needed.
Discuss the use of other medications with a pharmacist, including non-prescription medicines, vitamins, and herbal products. Some substances can interact with Nolvadex and may alter effectiveness or increase side effects. Do not start or stop any additional therapy without professional guidance.
Dental procedures or surgery should be reported to the clinician before the event. Some anaesthetics or medications used around dental work may interact with Nolvadex; professional advice will determine whether any adjustments are required.
Nolvadex tablets are not typically intended to be crushed or chewed unless specifically advised by a clinician. If swallowing becomes difficult, or if there is trouble with the tablet format, consult a pharmacist for alternatives or guidance.
Ongoing monitoring typically includes clinical review and may involve blood tests to assess organ function, liver enzymes, and overall treatment impact. A clinician will arrange follow-up imaging or other assessments as appropriate to the cancer profile and response to therapy. Any new symptoms reported between visits should be communicated promptly.
Menstrual status and reproductive considerations are discussed in premenopausal patients, with attention to potential changes during treatment. The possibility of climacteric symptoms or gynecological effects is considered as part of routine care, and management plans may be adjusted accordingly.
Bone health and cardiovascular risk are sometimes considered in long‑term hormone-modulating therapy. Preventive steps, such as lifestyle measures and nutrient balance, may be recommended in addition to medical treatment, depending on individual risk factors.
Patients should not discontinue Nolvadex without professional guidance, as abrupt changes can influence disease control and overall health. A plan for tapering or stopping the medication is provided by the clinician if therapy ends.
Use during pregnancy is generally avoided because of potential risks to the developing fetus. If pregnancy occurs or is possible during treatment, contact a clinician promptly to discuss options and alternatives. A plan for stopping or modifying therapy is typically required under professional guidance.
Breastfeeding during Nolvadex therapy is usually not recommended. Discuss breastfeeding plans with a clinician to determine the safest approach for both mother and baby.
Tablets are intended to be swallowed whole with water unless advised otherwise by a clinician. Splitting, crushing, or chewing tablets can change how the medication is absorbed and is not routinely recommended unless explicitly instructed.
Improvements in cancer control or reduction in recurrence risk are typically assessed over weeks to months, not days. Regular monitoring and imaging or other tests guide the evaluation of treatment response.
Moderate alcohol consumption is not universally contraindicated with Nolvadex, but heavy drinking can worsen certain side effects or interact with other aspects of care. Discuss personal consumption patterns with a clinician if there are concerns.
Some non-prescription medicines or herbal products can interact with Nolvadex. Report all medicines and supplements to a pharmacist or clinician to review potential interactions and adjust therapy if needed.
It is important to inform the dentist that Nolvadex is being taken, as the medication can influence healing and the risk profile for certain procedures. The dentist may adjust the plan or monitor closely as required.
If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to catch up. If multiple days are missed, contact a clinician for advice on how to resume safely.
Some antidepressants and pain medicines can interact with hormone-modulating therapies. Inform the treating clinician about all medicines, and avoid initiating new drugs without professional input.
Duration depends on the cancer type, stage, and response to therapy, as well as clinical guidelines. The plan is individualized and periodically reviewed by a clinician during follow-up visits.
Tamoxifen can influence hormonal balance and menstrual patterns in premenopausal individuals and may interact with menopausal symptoms. Fertility plans and hormone considerations should be discussed with a clinician as part of the treatment plan.
Routine monitoring may include liver function tests, blood counts, and assessment of any signs of adverse effects. Imaging or other disease-specific assessments may be scheduled to evaluate treatment impact over time.
Stopping and restarting therapy should only occur under medical supervision. A clinician may provide a plan for cessation and, if appropriate, guidance on resuming treatment after a defined interval or upon re‑evaluation.
Unused or expired tablets should be returned to a pharmacy or disposed of according to local guidance. Do not discard medications in household waste or drains unless advised by healthcare professionals.
Provide details of Nolvadex therapy to any new prescriber. Coordinated care helps prevent interactions and ensures the treatment plan remains appropriate for the patient’s health status and other therapies.
Renal or liver impairment can affect how the medicine is processed in the body. Such conditions are carefully considered by clinicians, who may adjust monitoring or dosing plans as needed.
In general, Nolvadex itself does not typically interfere with imaging results, but any ongoing cancer therapy should be discussed with the imaging team or oncologist to interpret findings accurately and plan follow-up appropriately.
Important signs include symptoms suggestive of blood clots (leg swelling, chest pain, sudden shortness of breath), yellowing of the skin or eyes, severe abdominal pain, persistent vomiting, or new severe headaches with vision changes. Report any such symptoms promptly to a clinician.
The primary sources of assurance are the prescribing clinician and the pharmacist who dispenses the medication. If questions arise outside routine hours, seek urgent medical guidance or contact a local healthcare service for advice.
14–21 days. Free from €178.99 .
5–9 days. €26.85
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
